Abstract
Isotretinoin safety reminderThe Medicines and Healthcare Products regulatory Agency (MHRA) has reminded prescribers to monitor patients treated with the retinoid isotretinoin for depression and to warn patients and their families to be alert for symptoms and suicidal thoughts (Drug Safety Update 2914;8(5):A2). The MHRA warns that stopping isotretinoin may not be enough to relieve symptoms and further psychiatric or psychological evaluation may be needed.Isotretinoin, available as the brands Roaccutane and Rizuderm, is licensed for the treatment of severe acne resistant to systemic antibacterials and topical therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
